SEC Filing | AbbVie
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update - IOS Press
AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application | ABBV Stock News
AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application | ABBV Stock News
アッヴィ、開発中のABBV-951（ホスカルビドパ/ホスレボドパ）について
ABBV-951（ホスレボドパ/ホスカルビドパ）が経口レボドパ
AbbVie (ABBV) Files NDA for Parkinson's Disease Candidate
AbbVie News Center - News
FDA snubs AbbVie's blockbuster-to-be Parkinson's drug
Months after FDA slam, AbbVie buys Parkinson's disease drugmaker Mitokinin
Produodopa (foscarbidopa/foslevodopa) / AbbVie
AbbVie files continuous Parkinson's therapy ABBV-951 in US | pharmaphorum
AbbVie launches pump-based Parkinson's drug in EU | pharmaphorum
Parkinson's disease Market Report 2032: Epidemiology, Therapies, Clinical Trials, Companies
Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion - IOS Press
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial - The Lancet Neurology
Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease - Rosebraugh - 2021 - Annals of Neurology - Wiley Online Library
AbbVie receives CRL over drug delivery device
FDA asks AbbVie for more information on Parkinson's treatment pump
Approval of Parkinson's therapy ABBV-951 delayed by FDA request | Parkinson's News Today
